ResMed (RMD), focused on medical equipment for the diagnosis and treatment of sleep-disordered breathing, provided encouraging results from a clinical study conducted with the new CPAP device. The trial, carried out on 50 sleep apnea patients found improved results with the new S9 series compared with the usual CPAP device.
Sleep apnea is a common sleep disorder with Obstructive sleep apnea (OSA) being the most common type of sleep apnea. In the latter case, the airway is obstructed during sleep, which is treated by Continuous Positive Airway Pressure (CPAP) therapy. However, this therapy has its own problems such as noise from the device, congestion and breathing discomfort, due to which ResMed has developed the improved S9 series.
Patients, after testing the S9 Series found it to be better than the current device with respect to breathing comfort, dryness of nose and mouth, and noise. Overall, 78% of the patients preferred the latest device.
ResMed reported revenues of $1.1 billion in fiscal 2010, up 19% (17% at constant exchange rates) from 2009. Growth in flow generators was mainly driven by strong sales of the recently launched S9 AutoSet and Elite products. Moreover, the company recorded strong growth of mask sales during the quarter.
During fiscal 2010, ResMed has released new products across mask and flow generator categories, which include Swift FX mask and the Mirage SoftGel mask apart from S9 products. The company has witnessed good response from patients related to the S9 launch. We expect the latest study data to further improve sales of these products.
RESMED INC (RMD): Free Stock Analysis Report
Zacks Investment Research
